PDCD1 and breast cancer: In this sense, metronomic paclitaxel combined with programmed cell death 1 (PD-1) mAb in a syngeneic breast cancer mouse model improved the anti-tumor efficacy of the immune checkpoint inhibitor as monotherapy, with a significant benefit in survival and reduced toxicity.